文献速递心脑血管急症重症综合管理与镇静镇痛

阻塞性冠状动脉疾病与经导管主动脉瓣置换术后健康状况:SCOPE I随机临床试验的事后分析

Obstructive Coronary Artery Disease and Health Status in Transcatheter Aortic Valve Replacement: A Post Hoc Analysis of the SCOPE I Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2025-12-01
一句话结论SCOPE I事后分析显示,接受TAVR的症状性重度主动脉瓣狭窄患者中,阻塞性CAD与3年生存、患者报告健康状况及VARC-3临床疗效无统计学显著差异。

该研究为SCOPE I随机临床试验的事后分析,纳入欧洲20家三级心脏中心732例接受TAVR的症状性重度主动脉瓣狭窄患者,按治疗人群分析。阻塞性CAD定义为至少1支主要心外膜冠状动脉狭窄大于50%,共373例(51.0%)存在阻塞性CAD,其中144例(38.6%)在围术期接受择期PCI。3年随访时,有无阻塞性CAD两组在患者报告健康状况(如KCCQ评分)、全因死亡(24.7% vs 22.3%,校正HR 0.97,95%CI 0.66-1.43)、心血管死亡(17.6% vs 15.5%,校正HR 0.87,95%CI 0.54-1.42)及VARC-3临床疗效(52.1% vs 53.4%,校正RR 1.10,95%CI 0.92-1.32)方面均无统计学显著差异。阻塞性CAD组心肌梗死风险数值上更高但未达统计学显著(5.5% vs 1.1%,校正HR 3.83,95%CI 0.96-15.31)。作者认为,对合并重度AS和CAD的TAVR候选者可能需要个体化治疗策略。

要点

  • 在732例接受TAVR的症状性重度AS患者中,阻塞性CAD(至少1支主要心外膜血管狭窄大于50%)占51.0%(373例)。
  • 3年全因死亡:有CAD组24.7% vs 无CAD组22.3%,校正HR 0.97(95%CI 0.66-1.43),无统计学显著差异。
  • 3年心血管死亡:有CAD组17.6% vs 无CAD组15.5%,校正HR 0.87(95%CI 0.54-1.42),无统计学显著差异。
  • 3年VARC-3临床疗效:有CAD组52.1% vs 无CAD组53.4%,校正RR 1.10(95%CI 0.92-1.32),无统计学显著差异。
  • 阻塞性CAD组围术期择期PCI(144/373,38.6%)未改善临床结局、患者报告健康状况或临床结局与生活质量综合终点。

适用人群与场景

  • 接受TAVR的症状性重度主动脉瓣狭窄患者,来自SCOPE I随机临床试验的治疗人群,平均(SD)年龄82(4)岁,女性416例(56.8%)。
  • 阻塞性CAD定义为至少1支主要心外膜冠状动脉狭窄大于50%,共373例(51.0%);无阻塞性CAD者359例。

诊断标准与关键阈值

  • 阻塞性CAD定义:至少1支主要心外膜冠状动脉狭窄大于50%。
  • 患者报告健康状况采用堪萨斯城心肌病问卷(KCCQ)评分,范围0至100分,分数越高表示健康状况越好。
  • 临床疗效采用瓣膜学术研究联盟(VARC)-3定义。

处置流程与药物剂量

  • 阻塞性CAD患者中144例(38.6%)在围术期接受择期经皮冠状动脉介入治疗(PCI)。

研究设计与关键结果

  • 研究类型:SCOPE I随机临床试验的事后分析,欧洲20家三级心脏中心,2017年2月8日至2019年2月2日,随访至3年。
  • 样本量:732例接受TAVR的症状性重度AS患者,按治疗人群分析;阻塞性CAD 373例(51.0%),无阻塞性CAD 359例。
  • 主要终点结果:3年全因死亡有CAD组24.7%(88/373) vs 无CAD组22.3%(76/359),校正HR 0.97(95%CI 0.66-1.43);心血管死亡有CAD组17.6%(59/373) vs 无CAD组15.5%(51/359),校正HR 0.87(95%CI 0.54-1.42)。
  • 患者报告健康状况:基线总体KCCQ中位数(IQR)有CAD组54.2(40.3-69.8) vs 无CAD组55.2(38.5-72.9);3年随访时有CAD组79.7(64.4-90.6) vs 无CAD组82.3(68.2-91.7),无统计学显著差异。
  • VARC-3临床疗效:有CAD组52.1%(163/313) vs 无CAD组53.4%(159/298),校正RR 1.10(95%CI 0.92-1.32),无统计学显著差异。
  • 心肌梗死:有CAD组5.5%(18/372) vs 无CAD组1.1%(3/359),校正HR 3.83(95%CI 0.96-15.31),数值上更高但未达统计学显著。
  • 阻塞性CAD患者围术期PCI未改善临床结局、患者报告健康状况或临床结局与生活质量综合终点。

证据类型、等级与局限

  • 证据类型:随机临床试验(SCOPE I)的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对合并重度AS和阻塞性CAD的TAVR候选者,可能需要个体化治疗策略。
  • 在本事后分析中,阻塞性CAD患者围术期择期PCI未改善临床结局、患者报告健康状况或综合终点。

指南或共识出处

  • SCOPE I随机临床试验(Safety and Efficacy of the Symetis ACURATE Neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis for Transcatheter Aortic Valve Implantation by Transfemoral Approach),ClinicalTrials.gov标识NCT03011346。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Aortic stenosis (AS) and obstructive coronary artery disease (CAD) often coexist, yet the impact of obstructive CAD on clinical and patient-reported outcomes in patients undergoing transcatheter aortic valve replacement (TAVR) remains a subject of ongoing debate.

OBJECTIVES: To investigate the association of obstructive CAD with clinical outcomes and health status among patients with symptomatic severe AS undergoing TAVR.

DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of the investigator-initiated, multicenter SCOPE I (Safety and Efficacy of the Symetis ACURATE Neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis for Transcatheter Aortic Valve Implantation by Transfemoral Approach) randomized clinical trial was conducted at 20 tertiary heart centers in Europe from February 8, 2017, to February 2, 2019, with follow-up through 3 years. Data were analyzed from February 17 through August 13, 2025.

EXPOSURE: Presence vs absence of obstructive CAD, defined as greater than 50% stenosis in at least 1 major epicardial coronary vessel.

MAIN OUTCOMES AND MEASURES: Parameters of interest included vital and patient-reported disease-specific health status (Kansas City Cardiomyopathy Questionnaire [KCCQ] scores, ranging from 0 to 100, with higher numbers indicating better health status), and clinical efficacy according to Valve Academic Research Consortium (VARC)-3 definitions. Analyses were conducted using the as treated population.

RESULTS: Of 732 patients with symptomatic severe AS undergoing TAVR (mean [SD] age, 82 [4] years; 416 [56.8%] female), obstructive CAD was identified in 373 (51.0%), 144 (38.6%) of whom underwent elective percutaneous coronary intervention (PCI) during the periprocedural period. At 3 years after TAVR, there were no statistically significant differences in patient-reported health status (eg, median [IQR] baseline overall KCCQ scores with CAD, 54.2 [40.3-69.8] vs without CAD, 55.2 [38.5-72.9] and at 3-year follow-up with CAD, 79.7 [64.4-90.6] vs without CAD, 82.3 [68.2-91.7]), mortality (all-cause death: 88 of 373 [24.7%] vs 76 of 359 [22.3%], adjusted hazard ratio, [HR], 0.97 [95% CI, 0.66-1.43]; cardiovascular death: 59 of 373 [17.6%] vs 51 of 359 [15.5%], adjusted HR, 0.87 [95% CI, 0.54-1.42]), and clinical efficacy of TAVR (163 of 313 [52.1%] vs 159 of 298 [53.4%]; adjusted risk ratio, 1.10 [95% CI, 0.92-1.32]) between patients with vs without obstructive CAD. Having (vs not having) obstructive CAD was associated with a numerically albeit not statistically significantly higher risk of myocardial infarction (18 of 372 [5.5%] vs 3 of 359 [1.1%]; adjusted HR, 3.83 [95% CI, 0.96-15.31]). Periprocedural PCI among patients with obstructive CAD did not improve clinical outcomes, patient-reported health status, nor the integrated end points of clinical outcomes and quality of life measures.

CONCLUSIONS AND RELEVANCE: In this post hoc analysis of SCOPE I, patients with obstructive CAD who underwent TAVR had no statistically significant differences in survival, patient-reported health status, or VARC-3 clinical efficacy compared with patients without CAD through 3 years of follow-up. Findings suggest that a tailored approach may be essential in the treatment of TAVR candidates with severe AS and CAD.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03011346.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Tomii D, Lanz J, Thiele H, et al. Obstructive Coronary Artery Disease and Health Status in Transcatheter Aortic Valve Replacement: A Post Hoc Analysis of the SCOPE I Randomized Clinical Trial. JAMA Netw Open. 2025. PMID: 41364435. doi:10.1001/jamanetworkopen.2025.47111

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。